Thus, before initiating treatment, high levels of IL-6, IL-8, IL-17, IL-33, TNF-α, TGF-β, and CRP in the circulation are strongly associated with increased glioma stem cell activity that potentially leads to glioma progression and greater invasiveness [49]. The gene discussed is IL33; the disease is central nervous system cancer.